Heart failure
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Initial tests
Fasting laboratory tests
- NT-proBNP
- FBC
- Serum sodium, serum potassium,
- Serum creatinine with eGFR
- Serum albumin
- Urea
- Lipid profile
- Fasting plasma glucose
- AST
- ALT
- GGT
- Alkaline phosphatase
- TSH
- Serum ferritin (if reduced ejection fraction)if needednon-French guidelineHeart failure with reduced ejection fraction: iron studies recommended by NICE (ferritin, transferrin saturation, haemoglobin), with intravenous iron to be discussed if ferritin < 100 ng/mL or transferrin saturation < 20% [2].
- Transferrin saturation (if reduced ejection fraction)if needednon-French guidelineSame indication as ferritin: iron deficiency defined by ferritin < 100 ng/mL or transferrin saturation < 20% [2].
- HbA1c (if known diabetes)if needednon-French guidelineNICE, ESC and the German recommendation (2019 chapter, under revision) list HbA1c alongside plasma glucose, or in its place for NICE; the HAS guide asks for plasma glucose [2,3,4,5].
Urine tests
- Urine dipstick (to look for a renal cause of the symptoms or an aggravating factor)if needednon-French guidelineNICE (to be considered, to look for an aggravating factor or another diagnosis), ACC/AHA/HFSA (class 1, expert opinion) and the German recommendation (2019 chapter, under revision) list urine tests; the 2014 HAS guide does not mention them [2,3,5,6].
Do not order
- Serum digoxin: do not measure routinely; useful only 8 to 12 hours after the last dose to confirm suspected clinical toxicity or non-adherence [2].
If signs of decompensation
Laboratory tests
- NT-proBNP
Do not order
- NT-proBNP or BNP at every routine check: HAS proposes it only if decompensation is suspected [3]; NICE advises measuring it to optimise treatment only in specialist care, before age 75, with a GFR > 60 mL/min/1.73 m² [2].
- BNP on sacubitril/valsartan: cannot be interpreted, as it is raised by the treatment itself [10].
Twice-yearly tests
Laboratory tests
- Serum electrolytes
- Serum creatinine with eGFR
- Urea
- Serum albumin
- FBCif neededIntercurrent event.
- ASTif neededIntercurrent event.
- ALTif neededIntercurrent event.
- GGTif neededIntercurrent event.
- Alkaline phosphataseif neededIntercurrent event.
- Serum ferritinif needednon-French guidelineNICE includes iron status and haemoglobin in the minimum follow-up of every heart failure (review at least every six months) [2].
- Transferrin saturationif needednon-French guidelineNICE includes iron status and haemoglobin in the minimum follow-up of every heart failure (review at least every six months) [2].
Do not order
- Routine serum digoxin: not recommended [2].
Starting or increasing an ACE inhibitor, ARB, sacubitril/valsartan or mineralocorticoid receptor antagonist
Before treatment
- Serum electrolytes
- Serum creatinine with eGFR
1 to 2 weeks after starting, then after each dose increase
- Serum electrolytes
- Serum creatinine with eGFR
Every 3 to 6 months at the maximum tolerated dose
- Serum electrolytes
- Serum creatinine with eGFR
Sources (12)
- Assurance maladie. Cartographie des pathologies et des dépenses, effectifs 2024 (data.ameli.fr, jeu « effectifs »), consulté le 24/10/2026.
- National Institute for Health and Care Excellence (NICE). Chronic heart failure in adults: diagnosis and management. Guideline NG106, septembre 2018, mise à jour 3 septembre 2025. Recommandations 1.2, 1.4.5-1.4.6, 1.7, 1.8.
- GUIDE DU PARCOURS DE SOINS Insuffisance cardiaque
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726.
- Bundesärztekammer, Kassenärztliche Bundesvereinigung, AWMF (Allemagne). Nationale VersorgungsLeitlinie Chronische Herzinsuffizienz, version longue 4.0, décembre 2023 (chapitre médicamenteux valable jusqu'au 12/12/2028 ; autres chapitres de 2019, validité échue le 22/10/2024, en révision).
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. J Am Coll Cardiol. 2022;79(17):e263-e421.
- Haute Autorité de santé. Place du coefficient de saturation de la transferrine pour le diagnostic de carence martiale dans les maladies chroniques avec composante inflammatoire. Rapport d'évaluation, validé en mai 2026, mis en ligne le 1er juin 2026.
- National Institute for Health and Care Excellence (NICE). Acute heart failure: diagnosis and management. Clinical guideline CG187, octobre 2014, mise à jour 17 novembre 2021.
- BNP, Nt-pro-BNP : lequel choisir en pratique ?
- Agence européenne des médicaments. Entresto (sacubitril/valsartan) : résumé des caractéristiques du produit, rubrique 4.4.
- Comment organiser la sortie des patients hospitalisés pour insuffisance cardiaque ?
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 du 2 juin 2026 : actes 1104 (hémogramme, B17) et 1821 (peptides natriurétiques, B45).